Evoke Pharma Inc
NASDAQ:EVOK

Watchlist Manager
Evoke Pharma Inc Logo
Evoke Pharma Inc
NASDAQ:EVOK
Watchlist
Price: 22.15 USD -0.23% Market Closed
Market Cap: 18.9m USD

Gross Margin
Evoke Pharma Inc

97%
Current
93%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97%
=
Gross Profit
14m
/
Revenue
14.4m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Evoke Pharma Inc
NASDAQ:EVOK
18.9m USD
97%
US
Eli Lilly and Co
NYSE:LLY
978.2B USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
485.6B USD
68%
CH
Roche Holding AG
SIX:ROG
257.9B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP
82%
US
Merck & Co Inc
NYSE:MRK
265B USD
79%
CH
Novartis AG
SIX:NOVN
207.5B CHF
76%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
82%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
68%
US
Pfizer Inc
NYSE:PFE
142.8B USD
75%
No Stocks Found

Evoke Pharma Inc
Glance View

Market Cap
18.9m USD
Industry
Pharmaceuticals

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

EVOK Intrinsic Value
136.49 USD
Undervaluation 84%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97%
=
Gross Profit
14m
/
Revenue
14.4m
What is the Gross Margin of Evoke Pharma Inc?

Based on Evoke Pharma Inc's most recent financial statements, the company has Gross Margin of 97%.

Back to Top